新型糖肽类抗生素海韦卡汀A和B。III. 生物学特性。

Helvecardins A and B, novel glycopeptide antibiotics. III. Biological properties.

作者信息

Takeuchi M, Katayama T, Inukai M

机构信息

Fermentation Research laboratories, Sankyo Co., Ltd., Tokyo, Japan.

出版信息

J Antibiot (Tokyo). 1991 Mar;44(3):278-81. doi: 10.7164/antibiotics.44.278.

DOI:10.7164/antibiotics.44.278

PMID:2026552

Abstract

Helvecardins (HVCs) A and B were strongly active against aerobic and anaerobic Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA), but they were inactive against Gram-negative bacteria and fungi. Though HVC A showed only slightly stronger antimicrobial activity than beta-avoparcin (AVP), its in vivo protective activity against S. aureus infection in mice was greatly superior to AVP.

摘要

Helvecardins（HVCs）A和B对包括耐甲氧西林金黄色葡萄球菌（MRSA）在内的需氧和厌氧革兰氏阳性菌具有很强的活性，但对革兰氏阴性菌和真菌无活性。尽管HVC A的抗菌活性仅比β-阿伏帕星（AVP）略强，但其对小鼠金黄色葡萄球菌感染的体内保护活性却大大优于AVP。